Characteristics and implications of mucopolysaccharidosis {#Sec1}
=========================================================

The mucopolysaccharidoses (MPSs) are lysosomal storage disorders, characterized by the functional deficiency caused by genetic mutation of one of the particular lysosomal enzymes which act in the sequential catabolism of glycosaminoglycans (GAGs, formerly known as mucopolysaccharides) (Wraith [@CR132]). Individuals with one of these rare metabolic disorders are affected by progressive accumulation of incompletely degraded GAGs within virtually all organ systems, although distribution varies depending on the specific disease (Wraith [@CR132]). The characteristics of the currently recognized MPS disorders and their subtypes are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Characteristics of all known MPS types with respect to demographics, patients' specifics and genetic/biochemical profile (Compiled from (Neufeld and Muenzer [@CR93]) and (Valayannopoulos et al. [@CR124]))MPS type (eponym)Incidence per 10^5^ live births; inheritance patternTypical age at diagnosisTypical life expectancy if untreatedEnzyme deficiencyGAGMPS I Hurler (H) MPS I Hurler-Scheie (H-S) MPS I Scheie (S)0.11-1.67; ARH: \< 1 year H-S: 3--8 years S: 10--20 yearsH: death in childhood H-S: death in teens or early adulthood S: normal to slightly reduced lifespanα-L-iduronidaseDS, HSMPS II (Hunter)0.1-1.07; XR1-2 years when rapidly progressingrapidly progressing: death \< 15 years slowly progressing: death in adulthoodiduronate-2-sulfataseDS, HSMPS III (Sanfilippo) A-B-C-D0.39-1.89; AR4-6 yearsdeath in puberty or early adulthoodheparan sulfamidase (A) N-acetyl-α-D-glucosaminidase (B) acetyl-CoA-α-glucosaminidase N-acetyltransferase (C) N-acetylglucosamine-6-sulfatase (D)HSMPS IV (Morquio) A-B0.15-0.47; AR1-3 yearsdeath in childhood- middle ageN-acetylgalactosamine-6-sulfatase (A) β-galactosidase (B)CS, KS (A) KS (B)MPS VI (Maroteaux-Lamy)0-0.38; ARrapidly progressing: 1--9 years slowly progressing: \> 5 yearsrapidly progressing: death in 2nd-3rd decade slowly progressing: death in 4-5^th^ decadeN-acetylgalactosamine-4-sulfataseDSMPS VII (Sly)0-0.29; ARneonatal to adulthooddeath in infancy- 4th decade\*\*β-D-glucuronidaseCS, DS, HSMPS IX (Natowicz)\*unknownadolescenceunknownhyaluronidaseCSAR: autosomal recessive; CS: chondroitin sulfate; DS: dermatan sulfate; GAG: glycosaminoglycan; H: Hurler syndrome; HS: heparan sulfate; H-S: Hurler-Scheie syndrome; KS: keratan sulfate; S: Scheie syndrome; XR: X-linked recessive\*only 1 patient reported in literature (Natowicz et al. [@CR91]); \*\*death can occur *in utero* with hydrops fetalis

Accumulation of partially-degraded GAGs progressively affects multiple organ systems and, possibly together with a cascade of secondary events, produces the classic phenotypes seen in these disorders. Typical manifestations include dwarfism (i.e. growth retardation), skeletal and joint deformities (e.g. dysostosis multiplex, including 'claw' hands), dysmorphic facial characteristics, central nervous system involvement (including mental retardation depending on type and severity, spinal cord compression and increased intracranial pressure), ocular (corneal clouding, retinal degeneration and blindness) and hearing impairment, respiratory difficulties, gastrointestinal pathology (e.g. hepatosplenomegaly, bowel dysfunction) and umbilical or inguinal hernias (Ferrari et al. [@CR23]; Garcia et al. [@CR27]; Lachman et al. [@CR63]; Wraith [@CR132]). The cardiovascular system is very commonly affected. While cardiac disease has been found in all of the MPS disorders, most studies indicate that it occurs earlier and more frequently in MPS I, II, and VI (Chen et al. [@CR17]; Dangel [@CR18]; Fesslová et al. [@CR24]; Gross et al. [@CR32]; Leal et al. [@CR65]; Mohan et al. [@CR84]; Wippermann et al. [@CR131]) than in MPS III or IV, while the frequency in MPS VII is difficult to judge due to the small number of patients.

Clinical findings and severity depend on the particular MPS syndrome, the specific genetic mutations involved (Karageorgos et al. [@CR52]; Matte et al. [@CR76]; Yogalingam et al. [@CR138]) and, to some extent, on the individual patient's biology with other, still undefined factors that lead to variability in phenotype within MPS syndromes. Based on severity and age at onset, some of the MPS syndromes have been categorized into slowly- and rapidly-progressing phenotypic subtypes (Jones et al. [@CR49]; Muenzer et al. [@CR89]; Neufeld and Muenzer [@CR93]; Schwartz et al. [@CR109]; Swiedler et al. [@CR115]; Thomas et al. [@CR121]). Phenotypic heterogeneity is seen in all types of MPS (Martins et al. [@CR73]; Muenzer et al. [@CR89]; Neufeld and Muenzer [@CR93]). The rapidly progressing form of MPS I (i.e. Hurler syndrome) is associated with central nervous system involvement and early-onset cardiac disease (Brosius and Roberts [@CR15]; Neufeld and Muenzer [@CR93]). Phenotypic severity, including mortality, in MPS II has been based, thus far, on the degree of developmental delay and GAG excretion (Jones et al. [@CR49]; Schwartz et al. [@CR109]). While central nervous system involvement does not play a role in MPS VI, phenotypic severity in somatic growth and pulmonary function has been correlated with urinary GAG excretion (Swiedler et al. [@CR115]).

Regardless of phenotype, all forms of MPS are associated with morbidity and early mortality (Table [1](#Tab1){ref-type="table"}) (Brosius and Roberts [@CR15]; Giugliani et al. [@CR29]; Jones et al. [@CR49]; Martins et al. [@CR73]). Premature death in untreated MPS syndromes is most commonly a result of respiratory compromise and cardiac disease (Chen et al. [@CR17]; Gross et al. [@CR32]; Jones et al. [@CR49]; Krovetz et al. [@CR61]). Reported cardiac causes of death include heart failure, sudden death from arrhythmias (including complete atrioventricular block) (Hishitani et al. [@CR43]; Martins et al. [@CR73]) and coronary occlusion (Lin et al. [@CR66]).

Cardiac disease associated with MPS {#Sec2}
===================================

Early reports {#Sec3}
-------------

Cardiac findings were not prominent in the earliest reports of Hurler syndrome (Hurler [@CR46]) and Hunter syndrome (Hunter [@CR45]). Beginning in the 1940-50s, detailed post-mortem cardiac studies on individuals clinically diagnosed with MPS (previously referred to as "gargoylism") were reported by several investigators (Emanuel [@CR21]; Lindsay [@CR67]; Strauss [@CR114]). These early morphologic studies occurred well before the biochemical basis of MPS disorders was established. It was only in 1965 that Victor McKusick, trained as a cardiologist and the father of modern medical genetics, established the classification of the MPS disorders based upon patterns of mucopolysacchariduria, a system that continues, with few changes, to be in use today (Kaplan [@CR51]; McKusick et al. [@CR80]; McKusick [@CR79]). The first MPS cardiac studies to include supporting biochemical data are those of Krovetz et al. (Krovetz et al. [@CR61]), Renteria et al. (Renteria et al. [@CR105]) and Brosius and Roberts (Brosius and Roberts [@CR15]).

Prevalence, severity and time of onset {#Sec4}
--------------------------------------

Because of the rarity of the disorders (Table [1](#Tab1){ref-type="table"}), cardiac studies involving large numbers of individuals with a particular MPS are uncommon. Nevertheless, the prevalence and severity of cardiovascular disease in individuals with MPS (especially MPS I, II and VI) is strikingly high, occurring in 60-100% of those studied (Chen et al. [@CR17]; Dangel [@CR18]; Fesslová et al. [@CR24]; Leal et al. [@CR65]; Martins et al. [@CR73]; Pastores et al. [@CR100]; Wippermann et al. [@CR131]). Cardiac valve involvement appears more common in those syndromes in which dermatan sulfate catabolism is deranged (MPS I, II and VI but not MPS III and IV) (Chen et al. [@CR17]; Dangel [@CR18]; Fesslová et al. [@CR24]; Leal et al. [@CR65]).

Within a particular type of MPS, cardiac pathology generally develops earlier in life for individuals with more rapidly progressing types of MPS (e.g. Hurler syndrome) (Brosius and Roberts [@CR15]; Hirth et al. [@CR42]) and may be delayed in slowly progressing forms (e.g. Hurler-Scheie and Scheie syndromes) (Soliman et al. [@CR113]). Nonetheless, cardiac disease is a uniformly progressive process (Chen et al. [@CR17]; Dangel [@CR18]; Fesslová et al. [@CR24]; Giugliani et al. [@CR29]; Krovetz et al. [@CR61]; Leal et al. [@CR65]; Mohan et al. [@CR84]; Muenzer et al. [@CR89]) with both incidence and severity increasing over time (Fesslová et al. [@CR24]). Despite this, clinical signs and symptoms of cardiac involvement are uncommon leading to an underestimate of the true prevalence of cardiac disease. For example, only six of 26 patients with documented echocardiographic disease presented with cardiovascular signs or symptoms (Dangel [@CR18]; Gross et al. [@CR32]; Leal et al. [@CR65]), a finding which underscores the importance of a complete cardiac evaluation after establishing a diagnosis of MPS.

Valvular disease {#Sec5}
----------------

Progressive cardiac valve pathology is the most prominent and uniform cardiac manifestation (60-90%) of patients with MPS (Fesslová et al. [@CR24]; Wippermann et al. [@CR131]). Cardiac valve thickening with associated dysfunction has been reported in more than 80% of patients with MPS I (including slowly progressing phenotypes) (Pastores et al. [@CR100]; Thomas et al. [@CR121]), 57% of patients with MPS II (Wraith et al. [@CR135]) and in all individuals with MPS VI except for the most slowly progressing ones (Azevedo et al. [@CR4]; Brooks et al. [@CR14]; Scarpa et al. [@CR108]).

Most studies have reported that valvular regurgitation, rather than stenosis, is more common and that the mitral valve, rather than the aortic, is most commonly affected. In general, left-sided valves (mitral & aortic) are more severely affected than those on the right side of the heart (tricuspid & pulmonary) (Dangel [@CR18]; Fesslová et al. [@CR24]; Krovetz et al. [@CR61]; Rigante and Segni [@CR106]; Thomas et al. [@CR121]). The mitral valve leaflets are markedly thickened and cartilage-like, with particularly thickened edges (Fig. [1](#Fig1){ref-type="fig"}). The subvalvular apparatus of the mitral valve develops shortened chordae tendineae and thick papillary muscles resulting in dysmorphic and poorly mobile leaflets (Fig. [1](#Fig1){ref-type="fig"}) (Tan et al. [@CR116]; Yano et al. [@CR137]). Calcific deposits commonly occur in the mitral annular region (Johnson et al. [@CR47]; Renteria et al. [@CR105]). The aortic valve presents a similar picture of progressive valve thickening and dysfunction (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1(**a**) Autopsy specimen from a female patient with Hurler syndrome at the age of 2.8 years showing (**a**) a dysplastic and thickened mitral valve (arrow) with a thickened subvalvular apparatus and parietal left ventricular hypertrophy and (**b**) a dysplastic aortic valve (arrow) (Fesslová et al. [@CR24]) (copyright Fesslová et al. Cardiol Young 2009)

These pathologic alterations result in regurgitation (insufficiency) and/or stenosis, both of which are easily identified by two-dimensional echocardiography and Doppler examination (Johnson et al. [@CR47]; Maganti et al. [@CR70]) (Fig. [2](#Fig2){ref-type="fig"}). Valvular stenosis or regurgitation may lead to left atrial and/or left ventricular volume overload, left ventricular dilatation, left ventricular hypertrophy (LVH), and ultimately to systolic and diastolic dysfunction. In a retrospective case series of children with various forms of MPS, LVH and diastolic dysfunction emerged at an early stage, whereas left ventricular dilation and systolic dysfunction occurred at older ages and later disease stage (Leal et al. [@CR65]) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 2Echocardiography and Doppler interrogation of mitral (**a**) and aortic (**b**) valve in a 50-year-old male with MPS VI (**a**) Short-axis view of thickened mitral valve (arrow) in diastole (left). Colour Doppler demonstration of mitral regurgitation (right). (**b**) Short-axis view demonstrating thickened trileaflet aortic valve (arrow) in systole (left). Colour Doppler demonstrating turbulent systolic flow of aortic valve stenosis (right)Fig. 3Echocardiographic evaluations in patients with MPS (2--14 years old, mean age 9 years; MPS I-II-III-IV-VI-VII) indicate that left valve lesions, left ventricular hypertrophy (LVH) and pulmonary hypertension are the most common cardiac findings (Leal et al. [@CR65]). AR: aortic regurgitation; MR: mitral regurgitation; MS: mitral stenosis; MR/MS: both lesions; \*LVH: septal and posterior wall hypertrophy of left ventricle

Coronary artery disease {#Sec6}
-----------------------

Coronary artery narrowing and/or occlusion has been described in individuals with all types of MPS (Braunlin et al. [@CR8]; Brosius and Roberts [@CR15]; Danks et al. [@CR19]; Factor et al. [@CR22]; Kettles et al. [@CR54]; Kurihara et al. [@CR62]; Renteria et al. [@CR105]; Shimamura et al. [@CR110]; Tan et al. [@CR116]), but is most common in MPS I and MPS II. Diffuse intimal proliferation from GAG deposition within large epicardial coronary arteries can occur early, especially in rapidly progressing MPS I (Brosius and Roberts [@CR15]), causing high-grade narrowing (Fig. [4](#Fig4){ref-type="fig"}). The lumens are nearly always central in location. Occlusion within coronary arterioles (rather than in the large epicardial coronary arteries) and a large left ventricular apical aneurysm have been described in an individual with MPS VI suggesting that different types of coronary involvement may occur in the various MPS syndromes (Oudit et al. [@CR98]). A similar apical aneurysm has been reported in MPS II (Kettles et al. [@CR54]), although a description of the coronary arterioles was not provided. Fig. 4Epicardial right coronary artery from untreated 1-year-old male with rapidly progressing MPS I. Note diffuse myointimal proliferation (arrow). (Alcian blue stain)

Other vascular changes {#Sec7}
----------------------

The great vessels in individuals with MPS may have increased wall thickness and may either be narrowed (Taylor et al. [@CR117]; Wraith et al. [@CR135]) or dilated (Hinek and Wilson [@CR41]). Diffuse narrowing of the thoracic and abdominal aorta (Taylor et al. [@CR117]) has been reported to occur in 30% of a small series of individuals with MPS I and II. Narrowing may occur at the aortic isthmus, a location typical for coarctation (Braunlin et al. [@CR9]), and may require surgical intervention for relief of significant obstruction. Although systemic hypertension due to arterial narrowing is common among individuals with MPS I and II (Taylor et al. [@CR117]; Wraith et al. [@CR135]), it has been less frequently noted in other types of MPS (including MPS VI) (Giugliani et al. [@CR29]).

Dilation of the ascending aorta and markedly reduced aortic elasticity has been reported in MPS I (Nemes et al. [@CR92]). This could be attributed to the downstream effects of GAGs on the assembly of tropo-elastin, resulting in elastin that is both decreased in content and abnormal in structure (Hinek and Wilson [@CR41]). Studies in MPS I and MPS VII animals have revealed that aortic dilation is likely due to degradation of elastin by matrix metalloproteinase-12 and/or cathepsin S (Ma et al. [@CR69]; Metcalf et al. [@CR81]). Aortic root replacement has not been reported for MPS patients to date.

Conduction abnormalities {#Sec8}
------------------------

Conduction abnormalities and sinus tachycardia have been reported in 44% of the patients with MPS VI and in 7% of a subset of the Hunter Outcome Survey of MPS II patients, respectively (Azevedo et al. [@CR4]; Wraith et al. [@CR135]). Several case reports have documented the development of complete atrioventricular block (MPS II, III and VI) with subsequent need for cardiac pacing and sudden death (Dilber et al. [@CR20]; Hishitani et al. [@CR43]; Misumi et al. [@CR83]). Fibrosis of the conduction system with GAG infiltration was seen in one individual with MPS VI who died suddenly (Keller et al. [@CR53]).

Underlying cardiac pathology {#Sec9}
============================

Although the pathobiology of MPS is incompletely understood, it is generally assumed that the influence of progressive GAG infiltration and its downstream effects are responsible for anatomical and functional alterations of the valves, coronary arteries, great vessels, conduction system and myocardium (Hinek and Wilson [@CR41]; Martins et al. [@CR73]).

Cardiac histopathology and electron microscopy are most complete in MPS I. These characteristically show increased GAG content as well as infiltration of 'clear' cells and granular cells within cardiac valves (leaflets, annuli and chordae tendineae), endocardium, myocardial walls, coronary arteries, aorta (Renteria et al. [@CR105]) and the conduction system (Hishitani et al. [@CR43]). Examination of heart tissue by light microscopy shows the morphological consequences of GAG storage, i.e. vacuolated cells with enlarged cytoplasm (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Light microscopy of the mitral valve of a girl with MPS VI at 14 years of age, demonstrating enlarged and foamy appearing fibroblasts (arrows) (hematoxylin and eosin staining, magnification x 20)

Role of GAGs in pathogenesis {#Sec10}
----------------------------

The heparan-, dermatan-, chondroitin- and keratan-sulfated GAGs are normal components of cardiac valves and the great vessels (Grande-Allen et al. [@CR31]; Gupta et al. [@CR34]; Latif et al. [@CR64]). Recent studies have implicated alterations in proteoglycan (GAG) metabolism in pathological processes such as myxomatous mitral valves (Grande-Allen et al. [@CR31]; Rabkin et al. [@CR104]), aortic aneurysm (Theocharis et al. [@CR120]), and atherosclerotic vasculature (Nakashima et al. [@CR90]). Dermatan-sulfated GAGs are a prominent component of normal cardiac valve tissue (Latif et al. [@CR64]) so it is not surprising to find a strong association between MPS I, II and VI (that result in the accumulation of dermatan-sulfated GAGs) and cardiac valve disease (Dangel [@CR18]; Leal et al. [@CR65]). Additionally, deep within the cardiac valves of all MPS syndromes, lie GAG-laden cells that have variously been called 'clear' cells, 'Gargoyle' cells or 'Hurler' cells. Recently, these cells have been identified in MPS I as being activated valvular interstitial cells engaged in attempted, but ineffective, valve repair (Braunlin et al. [@CR13]). The mechanisms by which the accumulated heparan-sulfated proteoglycans and attendant vascular interstitial cells affect the vasculature of the great vessels and coronary arteries in MPS I, II, and III (the heparan-sulfate accumulating MPS disorders) remains unknown. One hypothesis for the role of GAGs in cardiac disease could be that GAGs induce inflammation by activating the Toll-like receptor 4 pathway, leading to upregulation of degradative proteases (Simonaro [@CR111]).

Diagnosis and regular monitoring of cardiac disease in MPS {#Sec11}
==========================================================

Physical examination {#Sec12}
--------------------

The physical examination not only of young children, but also of adults with MPS is challenging due to both physical and, sometimes, intellectual patient limitations. A complete examination includes right upper as well as lower extremity blood pressures (to exclude aortic obstruction), pulse rate, palpation of pulses in all extremities, as well as careful auscultation of the heart and lungs. Other aspects of a complete cardiac examination, evaluating jugular venous distention or hepatosplenomegaly, may be unrewarding due to shortened necks and the presence of GAG-laden and enlarged visceral organs. Dysostosis multiplex and joint stiffening may complicate blood pressure measurements. Auscultation is often suboptimal due to pronounced upper airway noises. While the cardiac sounds are generally easily heard, the absence of cardiac murmurs does not exclude the presence of significant cardiac disease. Mild to moderate degrees of valvular stenosis and/or regurgitation can be present without significant murmurs.

Non-invasive techniques {#Sec13}
-----------------------

Because of its versatility, ease of performance and cost-effectiveness, transthoracic two-dimensional echocardiography is the primary imaging modality used to evaluate cardiac anatomy and function in patients with MPS (Aguilar et al. [@CR1]). Echocardiography provides reliable measurements of ventricular chamber dimensions (both systolic and diastolic) and left ventricular posterior and septal wall thicknesses, which can be normalized for body surface area. Accurate measures of ventricular function (shortening fraction & ejection fraction) can be determined. Doppler interrogation of cardiac valves allows accurate grading of valve stenosis and regurgitation as well as estimation of cardiac output and right ventricular/pulmonary artery pressures (Aguilar et al. [@CR1]). Despite its benefits, echocardiography provides only limited information in the assessment of coronary artery anatomy and pathology. Transthoracic echocardiography can usually be performed without sedation if the child is allowed to remain in his parent's arms or if he can be distracted by videos or toys. In some instances, however, transthoracic echocardiography may be suboptimal due to limited tolerance for examination, abnormal cardiac position, scoliosis, or hyper-aerated lung fields. Transesophageal echocardiography is not routinely employed in those with MPS as it requires monitored sedation or general anaesthesia, which may be poorly tolerated because of the airway complications that are not infrequent in this patient population.

Magnetic resonance imaging (MRI) and computed tomography (CT) are advanced techniques not routinely used for cardiac evaluation in children. Although MRI is a reliable tomographic technique for assessing cardiac anatomy and function (with quantification of volumetrics and regurgitation), its application is limited by heart rate constraints, slow acquisition times, and the need for sedation, and may be contraindicated in individuals with implanted devices (Aguilar et al. [@CR1]). Cardiac CT angiography, advantageous with respect to acquisition speed and resolution, is limited by relatively large radiation exposure and suboptimal assessment of valve morphology and hemodynamics (Aguilar et al. [@CR1]).

Evaluation for the presence of coronary arteriopathy in the MPS disorders is problematic because the diffuse nature of coronary involvement differs substantially from typical atherosclerotic coronary disease. While the latter is believed to be reliably [excluded]{.ul} by a normal CT angiogram (Taylor et al. [@CR119]), this may not be true in MPS coronary disease. Coronary angiography is therefore indicated in those suspected of having coronary artery pathology (Winchester et al. [@CR130]), but may miss significant disease due to the diffuse nature of the process in MPS (Braunlin et al. [@CR8]). Intravascular ultrasound has successfully identified significant coronary artery narrowing in adults with Fabry's disease (Kovarnik et al. [@CR58]), but has not been reported in the MPS disorders and remains primarily a research tool. The value of non-invasive dobutamine or adenosine stress testing combined with echocardiography or MRI imaging is currently under study in individuals with MPS.

Standard 12-lead electrocardiography (ECG) is the second most important technique used to evaluate the hearts of individuals with MPS. Assessment of heart rate and rhythm as well the determination of conduction times (PR interval, QRS duration, corrected QT interval) are all important clues to the health of the underlying conduction system. In instances where symptoms suggestive of either conduction block or arrhythmia are present, more prolonged monitoring (Holter or event monitor) is required for identifying arrhythmias and heart rate variability. Although rarely detected on routine ECG, one should pay attention for signs of ischemia in this patient population.

Recommendations {#Sec14}
---------------

Individuals with MPS should undergo physical examination, echocardiography and 12-lead ECG at the time of diagnosis, followed by regular monitoring (every 1 to 2 years for MPS I and VI, or 1 to 3 years for MPS II) thereafter in order to provide appropriate diagnosis and management (Giugliani et al. [@CR29]; Muenzer et al. [@CR88], [@CR89]). Additional cardiac evaluations should be considered before major operative interventions. Complete evaluation includes right arm and leg blood pressure measurements, careful auscultation, performance of a full transthoracic two-dimensional and Doppler echocardiogram, 12-lead ECG, and Holter monitoring as indicated (Giugliani et al. [@CR29]; Muenzer et al. [@CR88], [@CR89]). Performance and interpretation of echocardiography should be standardized (in terms of equipment and settings) and provided by individuals familiar with expected pathological findings in patients with MPS (Fig. [6](#Fig6){ref-type="fig"}). Fig. 6Recommended diagnostic techniques and assessments to evaluate cardiac anatomy and function in patients with MPS at initial diagnosis and at regular intervals thereafter (every 1 to 2 years for MPS I and VI, or 1 to 3 years for MPS II) 2D: 2-dimensional; ECG: electrocardiography; ECHO: echocardiography

Management of cardiac disease in MPS {#Sec15}
====================================

Current patient management is dependent upon the type of MPS present and may include standard pharmacological and surgical care, enzyme replacement therapy (ERT) or hematopoietic stem cell transplantation (HSCT). While standard medical care has focused on medications for heart failure and cardiac surgery (Valayannopoulos et al. [@CR124]), systemic therapies aim to restore functional enzyme and slow, or possibly reverse, disease progression. Systemic therapies have been shown to lengthen life (HSCT) and to improve clinical status (HSCT and ERT), particularly when performed early in life (Martins et al. [@CR73]; Muenzer et al. [@CR88]; Prasad and Kurtzberg [@CR103]; Valayannopoulos et al. [@CR124]).

Pharmacological and surgical approaches {#Sec16}
---------------------------------------

In the adult population, standard pharmacological and surgical management has been driven by cardiac pathophysiology regardless of MPS type. One longitudinal cohort study reported 33% of 48 patients with MPS received standard drug therapy for hemodynamic complications caused by valvular lesions or heart failure (Fesslová et al. [@CR24]). In the pediatric population, due to the absence of large-scale, long-term pharmacological studies, clear recommendations regarding pharmacologic management have not been defined (O'Connor et al. [@CR95]). Afterload reduction with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has been reported as useful in small series of non-MPS children with aortic or mitral regurgitation, hypertension or heart failure (O'Connor et al. [@CR95]). Although these drugs are frequently used, formal recommendations have yet to be made regarding their use in children, either with or without MPS (O'Connor et al. [@CR95]).

Progressive deposition of GAGs within the cardiac valves can lead to regurgitation or stenosis severe enough to require surgical intervention. Cardiac valve surgery is among the procedures frequently performed in patients with MPS (Arn et al. [@CR3]). Successful valve repair or replacement has been reported in individuals with all types of MPS (Table [2](#Tab2){ref-type="table"}). Mitral valve replacement was performed in MPS I (Kitabayashi et al. [@CR55]; Kraiem et al. [@CR59]), MPS II (Antoniou et al. [@CR2]) and MPS VI (Marwick et al [@CR74]); a 6-year-old with MPS III (Muenzer et al. [@CR86]) has undergone mitral valvuloplasty. Successful aortic valve replacement has been reported in adults with slowly progressing MPS I (Masuda et al. [@CR75]), MPS IV (Barry et al. [@CR5]; Nicolini et al. [@CR94]; Pagel and Almassi [@CR99]) and MPS VI (Wilson et al. [@CR128]). Due to pathological abnormalities in the native pulmonary root, the Ross procedure, where the aortic valve is replaced by the patient's own pulmonary valve, is contraindicated in individuals with MPS (Barry et al. [@CR5]). Combined aortic and mitral valve replacement was successfully performed in adults (Butman et al. [@CR16]; Fischer et al. [@CR25]; Minakata et al. [@CR82]) and in teens as young as 12 years of age (Goksel et al. [@CR30]) with MPS I and in adults with MPS II (Joly et al. [@CR48]) and MPS VI (Hachida et al. [@CR35]; Tan et al. [@CR116]). Fesslová et al. have reported favorable mitral and aortic valve replacement in three patients with Scheie syndrome and one with slowly progressing Hunter syndrome ranging in age from 13--53 years (Fesslová et al. [@CR24]). Other successful cardiac procedures include coronary artery bypass surgery in a 56-year-old male with slowly progressing MPS I (Minakata et al. [@CR82]), closure of an outlet type of ventricular septal defect in a child with MPS III (Kourouklis et al. [@CR57]), and repair of 'coarctation' of the aorta after HSCT in a 3-year-old boy with rapidly progressing MPS I (Braunlin et al. [@CR9]). Table 2Successful cardiac operative procedures in MPS disordersOperative procedure performedType MPS (patient age in years/gender)ReferencesMitral valve replacementI-S (41 F)(Kitabayashi et al. [@CR55])I-H (16 F)(Kraiem et al. [@CR59])II (33 M)(Antoniou et al. [@CR2])VI (25 F)(Marwick et al. [@CR74])Mitral valvuloplastyIII (6 F)(Muenzer et al. [@CR86])Aortic valve replacementI-S (62 M)(Masuda et al. [@CR75])IV (31 F; 41 M)(Nicolini et al. [@CR94]; Pagel and Almassi [@CR99])VI (43 M)(Wilson et al. [@CR128])Ross procedure\*IV (32 F)(Barry et al. [@CR5])Aortic and mitral valve replacementI (12 M)(Goksel et al. [@CR30])I-S (23-35 M; 42 F; 52 M)(Butman et al. [@CR16]; Fischer et al. [@CR25]; Minakata et al. [@CR82])II (18 M)(Joly et al. [@CR48])VI (21 F, 30 M, 34 F; 41 M)(Hachida et al. [@CR35]; Tan et al. [@CR116])Coronary artery bypassI-S (56 M)(Minakata et al. [@CR82])Ventricular septal defect closureIII (15 M)(Kourouklis et al. [@CR57])CoarctectomyI-H (3 M)(Braunlin et al. [@CR9])F: female; I-H: Hurler syndrome; I-S: Scheie syndrome; M: male\*aortic valve replacement by autologous pulmonary valve graft

While the long-term outcome is generally favorable (Hachida et al. [@CR35]; Marwick et al. [@CR74]; Tan et al. [@CR116]; Wilson et al. [@CR128]), candidacy for surgical intervention must be based on general health status and potential risks posed by intubation and post-operative care. Craniofacial abnormalities, excessive oral pharyngeal and upper airway tissue, a short stiff neck, and unstable atlantoaxial joint (with risk of spinal cord injury) (Giugliani et al. [@CR29]) may combine to complicate intubation and airway management in select patients (Walker et al. [@CR126]). Intubation with use of fiber-optic bronchoscope and expertise in dealing with uncommon airway issues in this patient population is often necessary. Endocarditis prophylaxis is currently recommended only in patients with a history of endocarditis, certain residual postoperative lesions, or a prosthetic valve (Maganti et al. [@CR70]; Wilson et al. [@CR129]).

Systemic therapies {#Sec17}
------------------

HSCT has been successfully employed for metabolic correction of MPS disorders for the past 30 years (Hobbs et al. [@CR44]; Krivit et al. [@CR60]). While this therapeutic approach has, in the rapidly progressing form of MPS I, significantly increased long-term survival and arrested neurologic deterioration (Orchard et al. [@CR97]), its beneficial effects in the remaining MPS disorders have not been proven (Prasad and Kurtzberg [@CR102], [@CR103]). Associated risks of HSCT are high (Boelens et al. [@CR7]; Prasad and Kurtzberg [@CR102], [@CR103]) and, as a consequence, HSCT is considered standard of care for only the most rapidly progressing forms of MPS I (Prasad and Kurtzberg [@CR102], [@CR103]).

Long-term metabolic correction by HSCT results in preservation of cardiac function and regression of cardiac hypertrophy (Braunlin et al. [@CR11]; Gatzoulis et al. [@CR28]; Guffon et al. [@CR33]; Krivit et al. [@CR60]; Viñallonga et al. [@CR125]). Cardiac valvular thickening is less likely to resolve (Herskhovitz et al. [@CR40]; Malm et al. [@CR71]) and left-sided valvular stenosis or regurgitation may remain unchanged (Yamada et al. [@CR136]) or progress (Braunlin et al. [@CR11]). Coronary artery narrowing and occlusion from myointimal proliferation in rapidly progressing MPS I appears to be arrested after successful HSCT (Braunlin et al. [@CR10]), a factor which may play a significant role in prolonged survival in these patients (Orchard et al. [@CR97]). The progression of cardiac valve pathology, despite successful engraftment after HSCT, is similar to disease progression in other relatively avascular sites such as bone and joint (Taylor et al. [@CR118]).

ERT, supplying exogenous human recombinant enzyme by regular intravenous infusion, is approved for three types of MPS; laronidase for MPS I (Wraith et al. [@CR133]), idursulfase for MPS II (Muenzer et al. [@CR87]) and galsulfase for MPS VI (Harmatz et al. [@CR36]; Harmatz et al. [@CR37]). Cross-correction with ERT is achieved in many organs and tissues, reflected by lower urinary GAG levels and symptomatic improvement. While galsulfase infusion has been shown to produce improvement in endurance (walk and stair climb test, sustained up to 5 years), pulmonary function, joint pain and stiffness, and growth and organomegaly (Harmatz et al. [@CR36]; Harmatz et al. [@CR37]; Harmatz et al. [@CR38]; Harmatz et al. [@CR39]), the outcome of ERT is less favorable for poorly vascularised or "privileged" sites (central nervous system, cornea, articular cartilage, and cardiac valves).

The effect of ERT alone on cardiac structure and function in patients with MPS is documented in only a few studies (Braunlin et al. [@CR12]; Fesslová et al. [@CR24]; Okuyama et al. [@CR96]; Scarpa et al. [@CR108]; Wraith et al. [@CR134]). As with HSCT, long-term ERT preserves, and may even improve (Hirth et al. [@CR42]), systolic ventricular function and results in resolution of ventricular hypertrophy in adults and children with MPS I and II (Braunlin et al. [@CR12]; Okuyama et al. [@CR96]; Wraith et al. [@CR134]). However, ERT does not appear to prevent progression of left-sided cardiac valve thickening and dysfunction (stenosis, regurgitation) in MPS I, II and VI. Stabilization of valvular disease in select patients over a limited study period has been observed (Braunlin et al. [@CR12]; Fesslová et al. [@CR24]; Okuyama et al. [@CR96]; Scarpa et al. [@CR108]). ERT has been used as an adjunct in MPS I to lower the GAG burden prior to HSCT (Tolar and Orchard [@CR122]) and, recently, galsulfase has been found to normalize mild elevations in GAG levels found in a single fully-engrafted patient with MPS VI 20 years after successful HSCT (Whitley and Utz [@CR127]). Whether these protocols will have beneficial cardiac effects remains unstudied.

In contrast to the young age at which most individuals with MPS undergo HSCT, ERT is usually begun in the older child (often after 5 years of age) with established cardiac valvular disease. It is possible that earlier use of ERT may prevent or ameliorate cardiac valve thickening and dysfunction in MPS as has been shown by two recent sibling studies (Gabrielli et al. [@CR26]; McGill et al. [@CR77]) (Table [3](#Tab3){ref-type="table"}). Each older sibling with either MPS I or MPS VI shared the same enzyme mutation as his younger sibling and differed only in the age at diagnosis. The older sibling in each instance, starting with ERT at 4 or 5 years of age, retained the classic phenotypical appearance of MPS as well as thickening, regurgitation or dysplasia of the mitral valve (Table [3](#Tab3){ref-type="table"}). By contrast, each younger sibling, treated with ERT from 8 weeks and 5 months of age and onwards, respectively, appeared phenotypically normal and had virtually no cardiac pathology by echocardiography either before, or after, ERT (Table [3](#Tab3){ref-type="table"}). These data underscore the importance of newborn or early screening for MPS as there appears to be a window in early infancy when ERT may prevent many of the end-organ manifestations of MPS. Table 3Impact of early initiation of enzyme replacement therapy (ERT) on the course of MPS according to open-label, case-control studies in sibling (sib) pairsStudy detailsSibling (gender)Echocardiographic abnormalitiesAt start of ERT (age)Post-ERT (age)MPS I Hurler-Scheie (Gabrielli et al. [@CR26]) 5 years ERT at 100 U/kg body weight weeklySib 1 (male)None (5 months)None (5 years and 5 months)Sib 2 (female)Moderate MR with thickened valve leaflets and anterior edge prolapsed; mild LA thickening (5 years)Stabilized cardiac function without improvement (10 years)MPS VI (McGill et al. [@CR77]) 3.5 years ERT at 1 mg/kg body weight weeklySib 1 (male)None (8 weeks)None (3.6 years)Sib 2 (female)Mild dysplastic mitral valve with trivial MR (3.6 years)Mild dysplastic mitral valve with trivial MR; mild AR (7.1 years)AR: aortic regurgitation; LA: left atrial; MR: mitral regurgitation

Future perspectives {#Sec18}
===================

A major step forward in the diagnosis and care of patients with MPS would be the development, implementation, and roll-out of a multi-tier screening procedure in newborns. This screening will identify pre-symptomatic newborns, allowing for early treatment and prevention or limitation of morbidity (Marsden and Levy [@CR72]). Continued efforts are being made to develop easy, reliable and specific blood and urinary tests for MPS detection based on enzyme activity, enzyme levels or GAG levels. After validation, it would be ideal if the existing newborn screening programme will be expanded to include MPS in addition to other lysosomal storage disorders.

Additionally, improvements in the choice of donor cells for HSCT may improve long-term results and result in lower procedure-induced mortality. In as much as cartilage and heart valves are both of mesenchymal origin, use of mesenchymal cells in conjunction with, or after, HSCT may provide potential to correct tissues currently unresponsive to either HSCT or cord blood transplantation alone (Boelens [@CR6]). A small number of patients with rapidly progressing MPS I have received mesenchymal cells in addition to HSCT (Koç et al. [@CR56]), but results were inconclusive and further research was recommended.

Finally, results with genetically modified viral vectors have shown prevention of cardiac valve pathology in dogs with MPS I or VII (Ponder et al. [@CR101]; Sleeper et al. [@CR112]; Traas et al. [@CR123]), in mice with MPS I that have very high serum enzyme after neonatal injection of a retroviral vector (Liu et al. [@CR68]), and in a mouse that received HSCT-directed gene therapy (Jordan et al. [@CR50]). The use of gene therapy, including autologous cells treated with viral vectors and then auto-transfused, remains untested in humans with MPS.

Concluding remarks {#Sec19}
==================

Progress in our understanding of MPS has increased significantly since Hunter and Hurler first reported their findings. Early case reports were methodically compiled and systematized by Victor McKusick into the classification scheme that has served us now for nearly 50 years (McKusick [@CR78]; McKusick et al. [@CR80]). Based upon the biochemistry of the disorders, the cardiac pathology and clinical findings of individual MPS disorders were then reported (Brosius and Roberts [@CR15]; Krovetz et al. [@CR61]; Renteria et al. [@CR105]). Successful HSCT was a pivotal event in the history of the MPS disorders (Hobbs et al. [@CR44]; Krivit et al. [@CR60]), providing long-term survival to children with a previously lethal disease, even though it was soon apparent that HSCT corrected some but not all disease features (Taylor et al. [@CR118]). The advent of two-dimensional echocardiography, occurring soon after successful HSCT, not only provided the basis for our understanding of the cardiac abnormalities (Dangel [@CR18]; Gross et al. [@CR32]; Wippermann et al. [@CR131]), but also became central in the evaluation of cardiac status before and after treatment. The development of ERT for MPS I, II and VI has significantly increased the number of individuals who can receive treatment for MPS including patients in whom HSCT may be either unavailable or inappropriate. Ongoing registries or surveillance programmes in MPS I, II, IV A and VI are beginning to provide large-scale international data on the scope and progression of various disease manifestations (Montaño et al. [@CR85]; Pastores et al. [@CR100]; Wraith et al. [@CR135]; <http://www.naglazyme.com/en/Clinical-resources/surveillance-program.aspx> - retrieved from 15 April 2011; <http://clinicaltrials.gov/ct2/show/NCT00214773?term=NCT00214773&rank=1> - retrieved from 15 April 2011) and may, in the future, serve as a mechanism for the evaluation of novel therapies.

Much remains to be learned about the heart and great vessels in MPS both before and after treatment. The natural history, cardiac findings, and pathology of all of the MPS (sub)types remains incomplete; defining specific MPS mutations associated with more severe cardiac pathology will improve and refine patient care. The development of neonatal screening for MPS will generate a need for answers to these and other questions.

Finally, because GAGs are an integral part of the cardiac valve and vasculature of normal hearts, the MPS disorders provide exquisite 'experiments of nature' that may yield insight into arenas as diverse as the development of autologous bioengineered cardiac valves (Sacks et al. [@CR107]) and the pathobiology of atherosclerotic cardiovascular disease (Nakashima et al. [@CR90]).
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